Clinical Trials For All’s Post

What does it take to drive meaningful progress in pediatric drug development? According to Christa Kerkorian, VP of Patient Advocacy at Day One, the answer lies in listening to the community and fostering multistakeholder collaboration. In this interview, hosted by Patients As Partners in Clinical Research Community News, Christa shares how insights from the pediatric cancer community inform Day One's advocacy approach and highlights key principles of engagement that guide these efforts. Read the full interview here: https://lnkd.in/gW2R_6e9

Multistakeholder collaboration is crucial to drug development in pediatric cancer. Christa Kerkorian, Day One Biopharmaceuticals, shares how her advocacy approach, directly informed by insights from the pediatric cancer community, led to a larger effort in multistakeholder collaboration between industry, academia, and nonprofits. Read the interview here: https://lnkd.in/gW2R_6e9 #PatientsasPartners2025 #pediatriccancer #cancerresearch #pharma #clinicalresearch #PatientAdvocacy #oncology #pediatriconcology

Are you aware that ~75% of anticancer drugs must be tested against pediatric cancer? 💊 It’s crucial to determine if your drug falls under this category.  The RACE Act addresses the gap in approved pediatric cancer treatments, by requiring adult oncology therapies to be tested for pediatric cancer use before FDA approval. Failure to consider the RACE Act early on could potentially disrupt progress during the IND stage. Access our 200+ well-characterized pediatric PDX models RACE Act-compliant (through ITCC-P4 consortium) to facilitate smoother transition to clinic.🚀 https://okt.to/1kpv4N #PediatricCancer #RACEAct #OncologyResearch #ClinicalTrials #DrugDevelopment 

Are you aware that ~75% of anticancer drugs must be tested against pediatric cancer? 💊 It’s crucial to determine if your drug falls under this category.  The RACE Act addresses the gap in approved pediatric cancer treatments, by requiring adult oncology therapies to be tested for pediatric cancer use before FDA approval. Failure to consider the RACE Act early on could potentially disrupt progress during the IND stage. Access our 200+ well-characterized pediatric PDX models RACE Act-compliant (through ITCC-P4 consortium) to facilitate smoother transition to clinic.🚀 https://okt.to/TNHJIz #PediatricCancer #RACEAct #OncologyResearch #ClinicalTrials #DrugDevelopment 

Are you aware that ~75% of anticancer drugs must be tested against pediatric cancer? 💊 It’s crucial to determine if your drug falls under this category.  The RACE Act addresses the gap in approved pediatric cancer treatments, by requiring adult oncology therapies to be tested for pediatric cancer use before FDA approval. Failure to consider the RACE Act early on could potentially disrupt progress during the IND stage. Access our 200+ well-characterized pediatric PDX models RACE Act-compliant (through ITCC-P4 consortium) to facilitate smoother transition to clinic.🚀 https://okt.to/MOtf1u #PediatricCancer #RACEAct #OncologyResearch #ClinicalTrials #DrugDevelopment 

Are you aware that ~75% of anticancer drugs must be tested against pediatric cancer? 💊 It’s crucial to determine if your drug falls under this category.  The RACE Act addresses the gap in approved pediatric cancer treatments, by requiring adult oncology therapies to be tested for pediatric cancer use before FDA approval. Failure to consider the RACE Act early on could potentially disrupt progress during the IND stage. Access our 200+ well-characterized pediatric PDX models RACE Act-compliant (through ITCC-P4 consortium) to facilitate smoother transition to clinic.🚀 https://okt.to/otHj6U #PediatricCancer #RACEAct #OncologyResearch #ClinicalTrials #DrugDevelopment 

Are you aware that ~75% of anticancer drugs must be tested against pediatric cancer? 💊 It’s crucial to determine if your drug falls under this category.  The RACE Act addresses the gap in approved pediatric cancer treatments, by requiring adult oncology therapies to be tested for pediatric cancer use before FDA approval. Failure to consider the RACE Act early on could potentially disrupt progress during the IND stage. Access our 200+ well-characterized pediatric PDX models RACE Act-compliant (through ITCC-P4 consortium) to facilitate smoother transition to clinic.🚀 https://okt.to/BnLHkw #PediatricCancer #RACEAct #OncologyResearch #ClinicalTrials #DrugDevelopment 

Are you aware that ~75% of anticancer drugs must be tested against pediatric cancer? 💊 It’s crucial to determine if your drug falls under this category.  The RACE Act addresses the gap in approved pediatric cancer treatments, by requiring adult oncology therapies to be tested for pediatric cancer use before FDA approval. Failure to consider the RACE Act early on could potentially disrupt progress during the IND stage. Access our 200+ well-characterized pediatric PDX models RACE Act-compliant (through ITCC-P4 consortium) to facilitate smoother transition to clinic.🚀 https://okt.to/dJ6chx #PediatricCancer #RACEAct #OncologyResearch #ClinicalTrials #DrugDevelopment 

Are you aware that ~75% of anticancer drugs must be tested against pediatric cancer? 💊 It’s crucial to determine if your drug falls under this category.  The RACE Act addresses the gap in approved pediatric cancer treatments, by requiring adult oncology therapies to be tested for pediatric cancer use before FDA approval. Failure to consider the RACE Act early on could potentially disrupt progress during the IND stage. Access our 200+ well-characterized pediatric PDX models RACE Act-compliant (through ITCC-P4 consortium) to facilitate smoother transition to clinic.🚀 https://okt.to/SGHzEN #PediatricCancer #RACEAct #OncologyResearch #ClinicalTrials #DrugDevelopment 

Are you aware that ~75% of anticancer drugs must be tested against pediatric cancer? 💊 It’s crucial to determine if your drug falls under this category.  The RACE Act addresses the gap in approved pediatric cancer treatments, by requiring adult oncology therapies to be tested for pediatric cancer use before FDA approval. Failure to consider the RACE Act early on could potentially disrupt progress during the IND stage. Access our 200+ well-characterized pediatric PDX models RACE Act-compliant (through ITCC-P4 consortium) to facilitate smoother transition to clinic.🚀 https://okt.to/UBlj12 #PediatricCancer #RACEAct #OncologyResearch #ClinicalTrials #DrugDevelopment